New drug oxacom® shows promise for treating rare lung condition
NCT ID NCT06683040
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new drug, Oxacom®, in 200 adults with pulmonary arterial hypertension (PAH), a serious lung condition that makes it hard to breathe. The drug is given in different doses to see if it can lower pressure in the lung's blood vessels better than a placebo. The goal is to control the disease and improve daily life.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PULMONARY ARTERIAL HYPERTENSION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
NMCRCardiologyRu
Moscow, 121552, Russia